SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Angiology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Hartmann, A.
Right arrow Articles by Tsuda, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hartmann, A.
Right arrow Articles by Tsuda, Y.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

A Controlled Study on the Effect of Pentoxifylline and an Ergot Alkaloid Derivative on Regional Cerebral Blood Flow in Patients with Chronic Cerebrovascular Disease

Alexander Hartmann

Neurologische Universitätsklinik Bonn, West Germany

Yoshiyasu Tsuda

Neurologische Universitätsklinik Bonn, West Germany

Regional cerebral blood flow (rCBF) in 90 patients with CBF decreased due to vascular diseases was studied by using the xenon 133 inhalation technique and a 32-detector setup. Whereas 30 patients received their standard basic ther apy only and were regarded as controls, 30 others received 3 x 2 mg/day of an ergot alkaloid (co-dergocrine mesylate), and 30 others received 3 x 400 mg pen toxifylline (slow-release formulation)/day orally. Therapy was performed for eight weeks and CBF measured before start of treatment, after a four-week treatment period, and at the end of the study. CBF did not change significantly in the control group; both the pentoxifylline and the ergot alkaloid group pre sented with a significant increase in the CBF. This positive effect was signifi cantly more pronounced in the pentoxifylline group and affected more ischemic than other brain tissues. In addition, symptoms like sleep disturbances, vertigo, and tinnitus improved significantly during the pentoxifylline observation peri od.

Angiology, Vol. 39, No. 5, 449-457 (1988)
DOI: 10.1177/000331978803900507
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 ANGIOLOGYHome page
P. L. Sonkin, L.-E. Chen, A. V. Seaber, and D. L. Hatchell
Vasodilator Action of Pentoxifylline on Microcirculation of Rat Cremaster Muscle
Angiology, June 1, 1992; 43(6): 462 - 469.
[Abstract] [PDF]

Home page
 ANGIOLOGYHome page
M. Armstrong JR, D. Needham, D. L. Hatchell, and R. S. Nunn
Effect of Pentoxifylline on the Flow of Polymorphonuclear Leukocytes Through a Model Capillary
Angiology, April 1, 1990; 41(4): 253 - 262.
[Abstract] [PDF]

Home page
 ANGIOLOGYHome page
R. Schneider
Results of Hemorheologically Active Treatment with Pentoxifylline in Patients with Cerebrovascular Disease
Angiology, November 1, 1989; 40(11): 987 - 993.
[Abstract] [PDF]


Advertisement